BCG Vaccines for Cancer Development Services
Online Inquiry

BCG Vaccines for Cancer Development Services

Fig.1 BCG Vaccines for Cancer Development Services.

BCG, initially employed for tuberculosis prevention, has garnered attention from researchers in recent years due to its potential applications in cancer therapy and prevention. Alfa Cytology is dedicated to delivering cutting-edge consulting services for cancer vaccine development, providing expertise across all stages of your research concerning BCG vaccines for cancer.

Introduction to BCG Vaccines

The BCG vaccine, initially developed in 1921 by French scientists Albert Calmette and Camille Guérin, is primarily utilized for tuberculosis prevention. Its application expanded in 1976 when it was introduced as an adjuvant therapy for non-muscle invasive bladder cancer. BCG is the gold standard for the therapy of non-muscle-invasive bladder cancer. Activated by BCG-associated pathogen-associated molecular patterns (PAMP) or damage-associated molecular patterns (DAMP) from apoptotic bladder cancer cells, a robust immune response is triggered, consistently recruiting cytotoxic leukocytes.

Fig.2 Introduction to BCG Vaccines.Fig. 1 BCG-trained cells increase cytotoxic leukocyte responses. (van Puffelen, J.H., et al., 2020)

Application of BCG Vaccines

There have been reliable studies that have found a significant role for BCG in inhibiting bladder cancer. In addition to this injection or oral administration of BCG can abate skin tumors to some extent. BCG has also been shown to play an active role in skin metastasis of breast and colon cancer, as well as in various skin-related cancers such as basal cell carcinoma, squamous cell carcinoma, lymphangiosarcoma, and reticulum-cell sarcoma. BCG vaccine is well tolerated in advanced non-small cell lung cancer against BCG cell wall skeleton (BCG-CWS) administered doses and is protective against childhood leukemia in the first year of life of young children, further demonstrating the pivotal role of BCG vaccines in anti-tumor research. If you are interested in any of the above cancer-related BCG vaccines, Alfa Cytology is waiting for your inquiry.

Our Service

Due to the potent inflammatory properties of BCG vaccines, they can instigate tumor-specific immunity. Alfa Cytology, a dedicated team specializing in cancer vaccine development, offers professional and dependable BCG vaccines for cancer.

BCG Vaccines Development Processes

Vaccine Strain Transmission

Following a specific cultivation period, the strains attain a particular density and activity level.

Vaccine Preparation

The inactivated strain is further processed to prepare it into a BCG vaccine.

Strain Cultivation

The initial phase of BCG vaccine production involves cultivating strains of Mycobacterium tuberculosis on specialized media.

Strain Inactivation

In the production of BCG vaccines, Mycobacterium tuberculosis strains are typically rendered inactive through heat or chemical treatments to ensure they do not pose a pathogenic risk to recipients.

Vaccine Quality Assurance

Stringent quality control measures are employed to assess the composition, purity, stability, and activity of the vaccine, ensuring it meets safety and efficacy standards.

Why Choose Us?

Professional and well-trained core technical team.

Professional and well-trained technical team.

Advanced experimental equipment.

Advanced experimental equipment.

Empowering success through cooperation.

Empowering success through cooperation.

Strict quality control system.

Strict quality control system.

BCG vaccines for cancer present an exciting avenue that holds promise for future cancer therapy. Alfa Cytology, consisting of seasoned scientists and biologists collaborating closely with global partners, provides comprehensive support services for the development of effective BCG vaccines against cancer, facilitating the advancement of your research endeavors. Feel free to contact us for support.


  1. van Puffelen, J.H., et al.; (2020). Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer. Nature reviews. Urology, 17(9), 513–525.
 For Research Only.